Claims for Patent: 10,328,130

Summary for Patent: 10,328,130

Title:	Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
Abstract:	Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.
Inventor(s):	Frost; Gregory I. (Del Mar, CA), Jiang; Ping (San Diego, CA), Thompson; Curtis B. (Encinitas, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	13/385,528
Patent Claims:	1. A method for treating a tumor with a PEGylated soluble human PH20 hyaluronidase in a subject having pancreatic cancer, comprising: a) measuring the expression or level of hyaluronan in a tumor sample from the subject, wherein the subject has pancreatic cancer; and the tumor sample is a pancreatic tumor biopsy sample; b) determining the level of expression of hyaluronan in the tumor biopsy sample; c) identifying, for treatment, the subject, wherein hyaluronan is expressed in at least 30% of the tumoral area in the tumor biopsy sample from the subject; and then d) administering to the subject, the PEGylated soluble PH20 hyaluronidase, and administering a second agent that is an anti-cancer agent or treatment for treating the tumor in the subject. 2. The method of claim 1, wherein the hyaluronan is detected with a hyaluronan-binding protein. 3. The method of claim 1, wherein the pancreatic cancer is selected from one or more of a late-stage pancreatic cancer, a metastatic pancreatic cancer or an undifferentiated pancreatic cancer. 4. The method of claim 1, wherein the PEGylated soluble human PH20 hyaluronidase is a C-terminally truncated human PH20 hyaluronidase that lacks all or a portion of a C-terminal GPI anchor. 5. The method of claim 1, wherein the PEGylated soluble PH20 hyaluronidase is: a polypeptide consisting of an amino acid sequence having at least 98% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 48, wherein the PEGylated soluble PH20 hyaluronidase is N-glycosylated and neutral active. 6. The method of claim 1, wherein the PEGylated soluble PH20 hyaluronidase consists of the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 95% amino acid sequence identity with the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of the amino acid sequence of SEQ ID NO: 1. 7. The method of claim 1, wherein the PEGylated soluble PH20 hyaluronidase is selected from a polypeptide consisting of the amino acid sequence set forth in SEQ ID NOS: 4-9 and 47-48, or variants thereof that have at least 98% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 48. 8. The method of claim 1, wherein PEGylation results from reaction with a PEG reagent selected from methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (5 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (30 kDa); methoxy-polyethylene glycol)-succinimidyl .alpha.-methylbutanoate (mPEG-SMB) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl .alpha.-methylbutanoate (mPEG-SMB) (30 kDa); methoxy-poly(ethylene glycol)-butyraldehyde (mPEG-butyraldehyde) (30 kDa), methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (30 kDa); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (10 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (20 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (40 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (60 kDa branched); biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) (5 kDa biotinylated); polyethylene glycol)-p-nitrophenyl carbonate (PEG-p-nitrophenyl-carbonate) (30 kDa); or poly(ethylene glycol)-priopionaldehyde (PEG-propionaldehyde) (30 kDa). 9. The method of claim 1, wherein the PEG is a branched or linear PEG. 10. The method of claim 1, wherein the PEG is a methoxy-PEG (mPEG). 11. The method of claim 1, wherein the PEG is a linear N-hydroxysuccinimidyl ester of methoxy poly(ethylene glycol) butanoic acid. 12. The method of claim 1, wherein the PEG has a weight of 30 kilodaltons. 13. The method of claim 1, wherein the PEGylated soluble PH20 hyaluronidase is administered intravenously, subcutaneously, intraperitoneally, or intra-tumorally. 14. The method of claim 1, wherein the PEGylated soluble PH20 hyaluronidase is administered at 10 to 50,000,000 Units. 15. The method of claim 1, wherein the anti-cancer agent or treatment is selected from the group consisting of a chemotherapeutic agent, radiation therapy, an antibody, a peptide, a gene therapy vector, a virus and a nucleic acid. 16. The method of claim 1, wherein the second agent is an anti-cancer agent selected from the group consisting of Acivicins; Aclarubicins; Acodazoles; Acronines; Adozelesins; Aldesleukins; Alemtuzumabs; Alitretinoins (9-Cis-Retinoic Acids); Allopurinols; Altretamines; Alvocidibs; Ambazones; Ambomycins; Ametantrones; Amifostines; Aminoglutethimides; Amsacrines; Anastrozoles; Anaxirones; Ancitabines; Anthramycins; Apaziquones; Argimesnas; Arsenic Trioxides; Asparaginases; Asperlins; Atrimustines; Azacitidines; Azetepas; Azotomycins; Banoxantrones; Batabulins; Batimastats; BCG Live; Benaxibines; Bendamustines; Benzodepas; Bexarotenes; Bevacizumab; Bicalutamides; Bietaserpines; Biricodars; Bisantrenes; Bisantrenes; Bisnafide Dimesylates; Bizelesins; Bleomycins; Bortezomibs; Brequinars; Bropirimines; Budotitanes; Busulfans; Cactinomycins; Calusterones; Canertinibs; Capecitabines; Caracemides; Carbetimers; Carboplatins; Carboquones; Carmofurs; Carmustines with Polifeprosans; Carmustines; Carubicins; Carzelesins; Cedefingols; Celecoxibs; Cemadotins; Chlorambucils; Cioteronels; Cirolemycins; Cisplatins; Cladribines; Clanfenurs; Clofarabines; Crisnatols; Cyclophosphamides; Cytarabine liposomals; Cytarabines; Dacarbazines; Dactinomycins; Darbepoetin Alfas; Daunorubicin liposomals; Daunorubicins/Daunomycins; Daunorubicins; Decitabines; Denileukin Diftitoxes; Dexniguldipines; Dexonnaplatins; Dexrazoxanes; Dezaguanines; Diaziquones; Dibrospidiums; Dienogests; Dinalins; Disermolides; Docetaxels; Dofequidars; Doxifluridines; Doxorubicin liposomals; Doxorubicin HCL; Docorubicin HCL liposome injection; Doxorubicins; Droloxifenes; Dromostanolone Propionates; Duazomycins; Ecomustines; Edatrexates; Edotecarins; Eflomithines; Elacridars; Elinafides; Elliott's B Solutions; Elsamitrucins; Emitefurs; Enloplatins; Enpromates; Enzastaurins; Epipropidines; Epirubicins; Epoetin alfas; Eptaloprosts; Erbulozoles; Esorubicins; Estramustines; Etanidazoles; Etoglucids; Etoposide phosphates; Etoposide VP-16s; Etoposides; Etoprines; Exemestanes; Exisulinds; Fadrozoles; Fazarabines; Fenretinides; Filgrastims; Floxuridines; Fludarabines; Fluorouracils; 5-fluorouracils; Fluoxymesterones; Flurocitabines; Fosquidones; Fostriecins; Fostriecins; Fotretamines; Fulvestrants; Galarubicins; Galocitabines; Gemcitabines; Gemtuzumabs/Ozogamicins; Geroquinols; Gimatecans; Gimeracils; Gloxazones; Glufosfamides; Goserelin acetates; Elydroxyureas; Ibritumomabs/Tiuxetans; Idarubicins; Ifosfamides; Ilmofosines; Ilomastats; Imatinib mesylates; Imexons; Improsulfans; Indisulams; Inproquones; Interferon alfa-gas; Interferon alfa-2bs; Interferon Alfas; Interferon Betas; Interferon Gammas; Interferons; Interleukin-2s and other Interleukins (including recombinant Interleukins); Intoplicines; Iobenguanes [131-1]; Iproplatins; Irinotecans; Irsogladines; Ixabepilones; Ketotrexates; L-Alanosines; Lanreotides; Lapatinibs; Ledoxantrones; Letrozoles; Leucovorins; Leuprolides; Leuprorelins (Leuprorelides); Levamisoles; Lexacalcitols; Liarozoles; Lobaplatins; Lometrexols; Lomustines/CCNUs; Lomustines; Lonafamibs; Losoxantrones; Lurtotecans; Mafosfamides; Mannosulfans; Marimastats; Masoprocols; Maytansines; Mechlorethamines; Meclorethamines/Nitrogen mustards; Megestrol acetates; Megestrols; Melengestrols; Melphalans; MelphalanslL-PAMs; Menogarils; Mepitiostanes; Mercaptopurines; 6-Mecaptopurine; Mesnas; Metesinds; Methotrexates; Methoxsalens; Metomidates; Metoprines; Meturedepas; Miboplatins; Miproxifenes; Misonidazoles; Mitindomides; Mitocarcins; Mitocromins; Mitoflaxones; Mitogillins; Mitoguazones; Mitomalcins; Mitomycin Cs; Mitomycins; Mitonafides; Mitoquidones; Mitospers; Mitotanes; Mitoxantrones; Mitozolomides; Mivobulins; Mizoribines; Mofarotenes; Mopidamols; Mubritinibs; Mycophenolic Acids; Nandrolonehenpropionates; Nedaplatins; Nelzarabines; Nemorubicins; Nitracrines; Nocodazoles; Nofetumomabs; Nogalamycins; Nolatrexeds; Nortopixantrones; Octreotides; Oprelvekins; Ormaplatins; Ortataxels; Oteracils; Oxaliplatins; Oxisurans; Oxophenarsines; Paclitaxels; Pamidronates; Patubilones; Pegademases; Pegaspargases; Pegfilgrastims; Peldesines; Peliomycins; Pelitrexols; Pemetrexeds; Pentamustines; Pentostatins; Peplomycins; Perfosfamides; Perifosines; Picoplatins; Pinafides; Pipobromans; Piposulfans; Pirfenidones; Piroxantrones; Pixantrones; Plevitrexeds; Plicamycid Mithramycins; Plicamycins; Plomestanes; Plomestanes; Porfimer sodiums; Porfimers; Porfiromycins; Prednimustines; Procarbazines; Propamidines; Prospidiums; Pumitepas; Puromycins; Pyrazofurins; Quinacrines; Ranimustines; Rasburicases; Riboprines; Ritrosulfans; Rituximabs; Rogletimides; Roquinimexs; Rufocromomycins; Sabarubicins; Safingols; Sargramostims; Satraplatins; Sebriplatins; Semustines; Simtrazenes; Sizoftrans; Sobuzoxanes; Sorafenibs; Sparfosates; Sparfosic Acids; Sparsomycins; Spirogermaniums; Spiromustines; Spiroplatins; Spiroplatins; Squalamines; Streptonigrins; Streptovarycins; Streptozocins; Sufosfamides; Sulofenurs; Sunitinib Malate; 6-thioguanine (6-TG); Tacedinalines; Talcs; Talisomycins; Tallimustines; Tamoxifens; Tariquidars; Tauromustines; Tecogalans; Tegafurs; Teloxantrones; Temoporfins; Temozolomides; Teniposides/VM-26s; Teniposides; Teroxirones; Testolactones; Thiamiprines; Thioguanines; Thiotepas; Tiamiprines; Tiazofurins; Tilomisoles; Tilorones; Timcodars; Timonacics; Tirapazamines; Topixantrones; Topotecans; Toremifenes; Tositumomabs; Trabectedins (Ecteinascidin 743); Trastuzumabs; Trestolones; Tretinoins/ATRA; Triciribines; Trilostanes; Trimetrexates; Triplatin Tetranitrates; Triptorelins; Trofosfamides; Tubulozoles; Ubenimexs; Uracil Mustards; Uredepas; Valrubicins; Valspodars; Vapreotides; Verteporfins; Vinblastines; Vincristines; Vindesines; Vinepidines; Vinflunines; Vinformides; Vinglycinates; Vinleucinols; Vinleurosines; Vinorelbines; Vinrosidines; Vintriptols; Vinzolidines; Vorozoles; Xanthomycin As (Guamecyclines); Zeniplatins; Zilascorbs [2-H]; Zinostatins; Zoledronate; Zorubicins; and Zosuquidars. 17. The method of claim 1, wherein the second agent and the PEGylated soluble PH20 hyaluronidase are administered in a single composition. 18. The method of claim 1, wherein the second agent and the PEGylated soluble PH20 hyaluronidase are administered separately. 19. The method of claim 1, wherein the second agent and the PEGylated soluble PH20 hyaluronidase are administered simultaneously, sequentially or intermittently in any order. 20. The method of claim 1, wherein the second agent is administered after administration of the PEGylated soluble PH20 hyaluronidase. 21. The method of claim 1, wherein the second agent is administered at least 24 hours after administration of the PEGylated soluble PH20 hyaluronidase. 22. The method of claim 1, wherein administration of the PEGylated soluble PH20 hyaluronidase and the second agent results in a reduction in tumor size and/or tumor volume compared to tumor size and/or tumor volume before administration of the PEGylated soluble PH20 hyaluronidase and the second agent. 23. The method of claim 22, wherein administration of the PEGylated soluble PH20 hyaluronidase and the second agent results in a reduction in tumor size compared to tumor size before administration of the PEGylated soluble PH20 hyaluronidase and the second agent. 24. The method of claim 22, wherein administration of the PEGylated soluble PH20 hyaluronidase and the second agent results in a reduction in tumor volume compared to tumor volume before administration of the PEGylated soluble PH20 hyaluronidase and the second agent. 25. The method of claim 22, wherein administration of the PEGylated soluble PH20 hyaluronidase and the second agent results in a reduction in tumor size and tumor volume compared to tumor size and tumor volume before administration of the PEGylated soluble PH20 hyaluronidase and the second agent. 26. The method of claim 1, wherein: the method comprises, prior to step a), obtaining a tumor sample from the subject. 27. The method of claim 1, wherein measurement is effected by immunohistochemistry. 28. The method of claim 1, wherein hyaluronan is expressed in at least 50% of the tumoral area of the tumor sample. 29. A method of treating a tumor in a subject having pancreatic cancer, comprising: a) identifying, for treatment, the subject with a tumor of a type in which hyaluronan is expressed in at least 30% of the tumoral area in a tumor sample, wherein; the subject has pancreatic cancer; and the sample is a pancreatic tumor biopsy sample; and then b) administering to the subject a PEGylated soluble human PH20 hyaluronidase, and administering a second agent that is an anti-cancer agent or treatment for treating the tumor in the subject, to thereby effect treatment. 30. The method of claim 29, wherein the second agent is a chemotherapeutic agent. 31. The method of claim 29, wherein hyaluronan is expressed in at least 50% of the tumoral area of the tumor sample.

Details for Patent 10,328,130

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2032-02-22
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2032-02-22
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2032-02-22
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2032-02-22
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	June 21, 1989		2032-02-22
Sanofi Pasteur Limited	THERACYS	bcg live	For Injection	103943	February 24, 2000		2032-02-22
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2032-02-22

International Patent Family for US Patent 10,328,130

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009128917
United States of America	2025222078
United States of America	2020368330
United States of America	2019336587
United States of America	2013028856
United States of America	2012171153
United States of America	2010003238